UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000030446
Receipt No. R000034219
Scientific Title Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetes
Date of disclosure of the study information 2019/01/01
Last modified on 2017/12/18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetes
Acronym Effect of SGLT2 inhibitor combined with metformin on body composition
Scientific Title Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetes
Scientific Title:Acronym Effect of SGLT2 inhibitor combined with metformin on body composition
Region
Japan

Condition
Condition type 2 diabetes mellitus
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To examine the changes of body composition and muscle strength between Dapagliflozin combined with or without metformin in patients with type 2 diabetes
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Comparison of the changes in total body muscle mass evaluated by dual-energy x-ray absorptiometry (DXA) before and after 24 weeks between the two groups
Key secondary outcomes Comparison of the changes in quadriceps muscle strength measured by a hand-held dynamometer before and after 24 weeks between the two groups

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Orally take a dose of 5mg of dapagliflozin once a day before or after breakfast in addition to the medicines taken at time of consenting.
If the blood glucose levels are high in patients after a month, it can be raised the dose of dapagliflozin to 10 mg once a day.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria 1)Type 2 diabetic patients with insufficient glycemic control (HbA1c 7.0 to 10.0%) and BMI 22 kg/m2 and over
2)Patients who are administrating more than or equal to 750mg of metformin, or who aren't receiving metformin thrapy
3)over 20 and under 65 years old
4)outpatient
5)male and female
Key exclusion criteria 1)patients who administrating less than 750mg of metformin
2)patients who receive insulin injection therapy
3)hypersensitivity to study drugs on this study,
4)severe ketosis and diabetic coma or pre-coma
5)serious infective diseases, serious injury, pre- and per-operation
6)pregnancy, nursing woman or possibly pregnant woman
7)moderate or severe renal dysfunction (eGFR: less than 30 mL/min/1.73m2)
8)patients who receive steroids, growth hormone secretagogue, sex hormone agents
9)patients who are inadequate to enter this study due to the other reasons by physician's judgments
Target sample size 54

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yasushi Tanaka
Organization St. Marianna University School of Medicine
Division name Division of Metabolism and Endocrinology, Department of Internal Medicine
Zip code
Address 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan
TEL 044-977-8111
Email y2tanaka@marianna-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hisashi Fukuda
Organization St. Marianna University School of Medicine
Division name Division of Metabolism and Endocrinology, Department of Internal Medicine
Zip code
Address 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan
TEL 044-977-8111
Homepage URL
Email h2fukuda@marianna-u.ac.jp

Sponsor
Institute St. Marianna University School of Medicine
Institute
Department

Funding Source
Organization 1)AstraZeneca K.K.
2)ONO PHARMACEUTICAL CO., LTD.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 01 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2017 Year 12 Month 18 Day
Date of IRB
Anticipated trial start date
2017 Year 12 Month 20 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 12 Month 18 Day
Last modified on
2017 Year 12 Month 18 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034219

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.